Arca
Skip to content

Miru 1day UpSide (midafilcon A)

Lenses, Soft Contact, Daily Wear. 510(k) K262495, from Menicon Co, Ltd. (Nagoya, JP). Product code LPL, class 2.

As of Nov 17, 2026, K262495 is an FDA 510(k) held by Menicon Co, Ltd., substantially equivalent on Sep 17, 2026 after 59 days, with no recalls tied to it in FDA's recall database.

  • Substantially equivalent: Sep 17, 2026
  • Review time: 59 days
  • Recalls: 0

Indications for Use

As the 510(k) summary states them, read from FDA's summary PDF

The Miru 1day UpSide (midafilcon A) SPHERICAL Lens is indicated for daily wear single use only for the optical correction of refractive ametropia (myopia and hyperopia) in aphakic and non-aphakic people with disease free eyes who may have 1.50 diopter (D) or less of astigmatism.

Predicate Devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Other LPL Clearances

The newest 510(k)s for the same product code; their median review was 146 days; see every LPL device

Record

Type
Traditional
Received
Jul 20, 2026
Review panel
Ophthalmic
Regulation
21 CFR 886.5925

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.